The emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how bivalent vaccines may improve antibody responses against new variants.
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.